KPT-9274选择性靶向NAMPT治疗急性髓系白血病
急性髓系白血病(AML)治疗选择有限且毒性显著。研究评估p21活化激酶4/NAMPT抑制剂KPT-9274的临床前活性,发现其通过耗竭NAD+诱导线粒体呼吸和糖酵解丢失及凋亡,减少集落形成、增加原始细胞分化、降低白血病起始细胞频率,对正常造血和免疫细胞毒性小,并在两种小鼠AML模型中改善总生存、在患者来源异种移植模型中减少肿瘤发展。
要点
- KPT-9274通过耗竭NAD+诱导AML细胞凋亡,不依赖突变和基因组异常。
- KPT-9274对正常造血或免疫细胞毒性极小。
- KPT-9274在两种小鼠AML模型中改善总生存,在患者来源异种移植模型中减少肿瘤发展。
核心结论
- KPT-9274在多种AML亚型中表现出广泛的临床前活性,作为AML潜在治疗药物值得进一步研究。
研究设计与样本
- 临床前研究:在AML细胞系、原代AML样本、两种小鼠AML模型及患者来源异种移植模型中评估KPT-9274的效应。
主要发现
- KPT-9274引发线粒体呼吸和糖酵解丢失,并诱导AML亚型凋亡,不依赖突变和基因组异常。
- 这些作用主要通过耗竭NAD+实现,而p21活化激酶4基因敲低未在AML细胞系中诱导细胞毒性,也未影响KPT-9274的细胞毒性效应。
- KPT-9274暴露减少集落形成、增加原始细胞分化、降低原代AML样本中白血病起始细胞频率。
- KPT-9274对正常造血或免疫细胞毒性极小。
- KPT-9274在两种不同小鼠AML模型中改善体内总生存,并在患者来源异种移植模型中减少肿瘤发展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment options for acute myeloid leukemia (AML) remain extremely limited and associated with significant toxicity. Nicotinamide phosphoribosyltransferase (NAMPT) is involved in the generation of NAD+ and a potential therapeutic target in AML. We evaluated the effect of KPT-9274, a p21-activated kinase 4/NAMPT inhibitor that possesses a unique NAMPT-binding profile based on in silico modeling compared with earlier compounds pursued against this target. KPT-9274 elicited loss of mitochondrial respiration and glycolysis and induced apoptosis in AML subtypes independent of mutations and genomic abnormalities. These actions occurred mainly through the depletion of NAD+, whereas genetic knockdown of p21-activated kinase 4 did not induce cytotoxicity in AML cell lines or influence the cytotoxic effect of KPT-9274. KPT-9274 exposure reduced colony formation, increased blast differentiation, and diminished the frequency of leukemia-initiating cells from primary AML samples; KPT-9274 was minimally cytotoxic toward normal hematopoietic or immune cells. In addition, KPT-9274 improved overall survival in vivo in 2 different mouse models of AML and reduced tumor development in a patient-derived xenograft model of AML. Overall, KPT-9274 exhibited broad preclinical activity across a variety of AML subtypes and warrants further investigation as a potential therapeutic agent for AML.
引用
- Mitchell SR, Larkin K, Grieselhuber NR, et al. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv. 2019. PMID: 30692102. doi:10.1182/bloodadvances.2018024182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。